Abstract:Abstract Background Blood‐based biomarkers of Alzheimer’s disease (AD) may provide an avenue for early identification of individuals at risk for AD dementia, which is a crucial task for implementing upcoming disease‐modifying therapies in clinical practice. Among blood‐based biomarkers, P‐tau217 has shown a particular sensitivity to amyloid pathology and utility for differential diagnosis of AD. However, less is known about the association of P‐tau217 with dementia risk in older primary care patients. Method To address this question in an extreme phenotype design, we measured plasma P‐tau217 using the validated ALZPath pTau217 assay developed on the Single molecule array (Simoa) technology in 184 patients (median age = 83 years) free of dementia at blood draw who converted to clinically diagnosed dementia of the Alzheimer’s type (DAT) during up to eight years of follow‐up. Furthermore, P‐tau217 was measured in 184 age‐ and sex‐matched cognitively normal controls that stayed free of any cognitive impairment during follow‐up. All participants were derived from the primary care‐based AgeCoDe‐cohort. In addition, Aβ 42 /Aβ 40 , P‐tau181, NfL, and GFAP were quantified using Simoa technology. Associations between P‐tau217 and conversion to DAT were assessed using conditional logistic regression and compared to associations of conversion to DAT with Aβ 42 /Aβ 40 , P‐tau181, NfL, and GFAP. The influence of time to DAT diagnosis on the associations was assessed by generalized additive models. Result P‐tau217 was strongly associated with conversion to DAT (OR per‐1SD‐increase [95%‐CI] = 10.29 [5.16‐20.41], p = 2.0*10 −11 , N = 368). This association was present irrespective of whether DAT‐converter showed MCI (OR per‐1SD‐increase [95%‐CI] = 3.49 [1.34‐9.12], p = 1.1*10 −2 ) or no MCI (OR per‐1SD‐increase [95%‐CI] = 16.07[6.54‐39.71], p = 1.3*10 −9 ) at blood draw. No other marker showed a similarly strong association with conversion (second‐best performance: GFAP; OR per‐1SD‐increase [95%‐CI] = 1.36 [1.19‐1.54], p = 2.15*10 −2 ). Patients converting to DAT eight years after blood draw already presented with elevated P‐tau217 levels compared to their matched controls. Other markers (GFAP, P‐tau181) started to show differences in individuals converting to DAT four years after blood draw. Conclusion P‐tau217 is the most sensitive plasma marker for risk of conversion to DAT in older patients from primary care patients in comparison to plasma P‐tau181, Aβ 42 /Aβ 40 , NfL, and GFAP.

P‐tau217 is the earliest plasma marker of dementia of the Alzheimer’s type in older primary care patients